Although our findings are consistent with the notion that oral FFAR1 agonists may constitute future L-cell stimulants for T2DM and obesity treatment, they also show that the mechanisms involved are more complicated than anticipated and appears to require appearance of the FFAR1 ligands in the circulation. Here, FFAR1 is linked to obesity due to melanocortin 4 receptor deficiency.